Clinical Trial Update: Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AFQ056 for reducing L-dopa-induced dyskinesias in Parkinson's disease and its safety when used with L-dopa; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED